Opinion

Video

Emerging Serum, Urine, and Tissue Biomarkers in the Clinical Setting

Author(s):

Benjamin H. Lowentritt, MD, FACS,Brian Richardson, MD

Prostate cancer management experts share their clinical insights on selecting appropriate serum, urine, and/or tissue biomarkers, highlighting specific scenarios that warrant each type of test.

Video content above is prompted by the following question:

  • In your clinical practice, are there specific situations in which you would choose serum, urine and/or tissue biomarkers? If so, can you expand on when you might use them?
Related Videos
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Related Content
Radioligand therapy shows promising safety in patients with mCRPC
March 13th 2025

Radioligand therapy shows promising safety in patients with mCRPC

Hannah Clarke
The mean absorbed radiation dose to tumors was 8.9 Gy/GBq, compared with 0.27 Gy/GBq in the kidneys and 0.13 Gy/GBq in the salivary glands.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC
March 10th 2025

Adding ADT to SBRT improves progression-free survival in oligorecurrent HSPC

Hannah Clarke
"Considering that almost all patients in the combined treatment group achieved testosterone recovery at 1 year, the results support that this short term (intermittent) combined approach is an optimal option in selected patients with metachronous oligorecurrent hormone-sensitive prostate cancer," the authors wrote.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC
March 4th 2025

Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC

Hannah Clarke
The median OS was 34 months with 177Lu-PSMA-617 plus enzalutamide compared with 26 months with enzalutamide alone.
FDA updates in urology: February 2025
March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke
A recap of the FDA submissions and regulatory decisions in urology from February 2025.
© 2025 MJH Life Sciences

All rights reserved.